ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
This article was originally published in The Pink Sheet Daily
Executive Summary
Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.
You may also be interested in...
Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.
Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.
ArQule Gets Early-Stage Cancer Program Back From Daiichi
The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.